KI67
A Key Biomarker in AI-Powered Breast Cancer Detection
%
Faster
Reduction in KI-67 scoring time compared to manual methods, with 98% concordance.
KI67: AI-Driven Biomarker Analysis
Artificial intelligence enhances KI67 analysis, providing more accurate insights into breast cancer proliferation for early detection and better diagnosis.
Our Mission
At DigPatho, we are committed to revolutionizing breast cancer detection through artificial intelligence. By leveraging advanced AI models, we enhance the analysis of biomarkers like KI67, providing more accurate and efficient diagnostic support. Our goal is to empower healthcare professionals with cutting-edge technology, enabling early detection and better treatment decisions for improved patient outcomes.
Programs
Current Initiatives & Projects
Breast Cancer Biomarkers: Diagnostic & Prognostic Precision
Our platform leverages AI-powered analysis of KI-67, delivering reproducible, clinically actionable insights to guide personalized treatment decisions.
Transforming Digital Pathology with AI
Harness the predictive power of biomarkers like KI-67 with cutting-edge algorithms for faster, objective, and more accurate breast cancer assessments.
Your Partner in Oncologic Diagnostics
From KI-67 quantification to HER2 interpretation, our technology enhances diagnostic efficiency and improves patient outcomes.
DigPatho
Diving into the Numbers
%
Over 70% of aggressive breast cancers show high KI-67 proliferation rates – our AI detects them with 99.8% accuracy
More than 500 cellular patterns linked to KI-67 expression are analyzed in real-time, revealing hidden prognostic insights.
Our database includes 1.5 million annotated tumor cells, training algorithms to predict treatment responses faster than traditional methods